Brief: Glenmark Pharma Says Ichnos Glenmark Innovation (IGI), Abbvie Announce Exclusive Global Licensing Agreement
10/07/2025 12:40
July 10 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: ICHNOS GLENMARK INNOVATION (IGI) AND ABBVIE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT LICENSING AGREEMENT FOR ISB 2001 IGI WILL RECEIVE AN UPFRONT PAYMENT OF $700 MILLION, ELIGIBLE TO RECEIVE UP TO $1.225 BILLION Source text: ID:nBSE3Lp8jW Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter